πŸ‡ΊπŸ‡Έ FDA
Patent

US 11229681

Dominant-negative FGF2 antagonists

granted A61KA61K38/1825A61P

Quick answer

US patent 11229681 (Dominant-negative FGF2 antagonists) held by The Regents of the University of California expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/1825, A61P, A61P35/00